"CEO says LTC is now positive and the rest of Genworth is growing well."
I have the earnings call transcript open, as well as the presentation. Where did the CEO say this?
I feel like you might need to be an actuary to digest this info.
If Gilead ever does make an acquisition announcement, expect the stock to catapult based on their past history of making excellent deals.
Pharmasset was overvalued too.
Look at TEVA today. They are offering a hefty premium for Mylan and the stock is rising.
I'd like to see the results from the quarter and then figure out my target price. My position is still small. Thanks for the feedback though.
I'm back in this one. Once the discounting questions are resolved, this stock will move up. Also, the PE ration is about to go from 13 to 10 when earnings are announced.
Please share this article on other sites and visit the Investors Unite site to see what else is happening.
December 8, 2014, 11:29 A.M. ET
Gilead Sciences: How Much Will You Pay for Its Hepatitis C Drugs?
By Ben Levisohn
If you’re the U.S. Department of Veterans Affairs, it’s about half the list price. Morgan Stanley’s Matthew Harrison and team look at the discount the VA is receiving on Gilead Sciences’ (GILD) hepatitis-c drugs Sovaldi and Harvoni:
Based on recent congressional testimony (Michael Valentino’s statement before the VA), the VA’s net price for [Gilead's] Sovaldi is $539/day, a ~50% discount to the list price (WAC) of $1,000.
Sky-High Price Has VA Rationing Drugs
December 18, 2014 | Tom Philpott
MILITARY UPDATE: Sky-High Price Has VA Rationing New Hepatitis C Drug
Sen. Bernie Sanders (I-Vt.) used one of his last hearings as chairman of the Senate Veterans Affairs Committee to review how VA has had to ration a break-through medicine that cures hepatitis C, a liver virus infecting 174,000 veterans, because a course of treatment – 84 pills over 12 weeks — costs VA almost $50,000 per patient.
If the after hours sell off is due to public payor discounts, people should refer to the news from mid-December about VA pricing. It's old news. Professional analysts put this info in their models already.
By the way, the company said 250,000 US patients in 2015. Volume is going to ramp up.
5% of the 1.5 billion shares, or 75 million shares, is held by non-institutional investors. At $106 per share, the non-institutional float is worth $8 billion. Where will they find $15 billion of stock to buy back?
Thank you Gilead
$125 coming soon